Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS


Share on StockTwits

Oramed Pharmaceuticals (NASDAQ:ORMP) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.09), Fidelity Earnings reports. Oramed Pharmaceuticals had a negative return on equity of 28.75% and a negative net margin of 230.07%.

ORMP traded down $0.12 on Friday, reaching $4.34. The company had a trading volume of 8,185 shares, compared to its average volume of 164,833. Oramed Pharmaceuticals has a 1 year low of $2.40 and a 1 year high of $5.71. The stock has a market capitalization of $102.75 million, a PE ratio of -13.51 and a beta of 1.58. The stock has a 50-day moving average price of $4.28 and a 200-day moving average price of $3.45.

Separately, Alliance Global Partners started coverage on shares of Oramed Pharmaceuticals in a research report on Thursday, December 3rd. They issued a “buy” rating and a $11.00 price target for the company.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.

Recommended Story: What is an Initial Public Offering (IPO)?

Earnings History for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.